25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Pharming Group NV
Buy, Hold or Sell?

Let's analyze Pharming together

I guess you are interested in Pharming Group NV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Pharming Group NV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Pharming Group NV

I send you an email if I find something interesting about Pharming Group NV.

Quick analysis of Pharming (30 sec.)










What can you expect buying and holding a share of Pharming? (30 sec.)

How much money do you get?

How much money do you get?
‚ā¨0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
‚ā¨0.28
Expected worth in 1 year
‚ā¨0.29
How sure are you?
67.5%

+ What do you gain per year?

Total Gains per Share
‚ā¨0.01
Return On Investment
1.2%

For what price can you sell your share?

Current Price per Share
‚ā¨0.77
Expected price per share
‚ā¨0.722 - ‚ā¨0.914
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Pharming (5 min.)




Live pricePrice per Share (EOD)

‚ā¨0.77

Intrinsic Value Per Share

‚ā¨-0.71 - ‚ā¨0.18

Total Value Per Share

‚ā¨-0.43 - ‚ā¨0.46

2. Growth of Pharming (5 min.)




Is Pharming growing?

Current yearPrevious yearGrowGrow %
How rich?$205.9m$200.9m$7.7m3.7%

How much money is Pharming making?

Current yearPrevious yearGrowGrow %
Making money-$2.6m-$498.7k-$2.1m-81.5%
Net Profit Margin-4.7%-1.8%--

How much money comes from the company's main activities?

3. Financial Health of Pharming (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#260 / 982

Most Revenue
#110 / 982

Most Profit
#336 / 982

Most Efficient
#331 / 982
3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Pharming? (5 min.)

Welcome investor! Pharming's management wants to use your money to grow the business. In return you get a share of Pharming.

What can you expect buying and holding a share of Pharming?

First you should know what it really means to hold a share of Pharming. And how you can make/lose money.

Speculation

The Price per Share of Pharming is ‚ā¨0.765. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Pharming.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Pharming, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ‚ā¨0.28. Based on the TTM, the Book Value Change Per Share is ‚ā¨0.00 per quarter. Based on the YOY, the Book Value Change Per Share is ‚ā¨0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ‚ā¨0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Pharming.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share
Usd Eps-0.02-2.4%0.00-0.5%0.00-0.1%0.000.6%0.000.0%
Usd Book Value Change Per Share-0.02-2.4%0.000.3%0.000.5%0.011.2%0.011.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.02-2.4%0.000.3%0.000.5%0.011.2%0.011.0%
Usd Price Per Share1.11-1.18-1.13-1.13-0.86-
Price to Earnings Ratio-15.02-34.51--0.31--4.28--0.58-
Price-to-Total Gains Ratio-60.67-222.38-1,309.93-329.18-130.68-
Price to Book Ratio3.63-3.82-3.84-4.75-10.41-
Price-to-Total Gains Ratio-60.67-222.38-1,309.93-329.18-130.68-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.83385
Number of shares1199
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.01
Usd Total Gains Per Share0.000.01
Gains per Quarter (1199 shares)2.9411.43
Gains per Year (1199 shares)11.7545.73
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1012204636
20241409182
3035260137128
4047380183174
5059500229220
6071620274266
7082740320312
8094860366358
90106980412404
1001181100457450

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%7.05.00.058.3%15.05.00.075.0%22.018.00.055.0%22.039.00.036.1%
Book Value Change Per Share3.01.00.075.0%9.03.00.075.0%16.04.00.080.0%27.013.00.067.5%35.022.04.057.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.061.00.0%
Total Gains per Share3.01.00.075.0%9.03.00.075.0%16.04.00.080.0%27.013.00.067.5%35.022.04.057.4%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Pharming

About Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Fundamental data was last updated by Penke on 2024-07-07 20:11:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of Pharming Group NV.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit¬†Pharming earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare¬†Pharming to the¬†Biotechnology industry mean.
  • A Net Profit Margin of -22.4%¬†means that¬†€-0.22 for each €1¬†in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Pharming Group NV:

  • The MRQ is -22.4%. The company is making a huge loss. -2
  • The TTM is -4.7%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ-22.4%TTM-4.7%-17.7%
TTM-4.7%YOY-1.8%-2.8%
TTM-4.7%5Y7.7%-12.4%
5Y7.7%10Y-24.8%+32.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-22.4%-169.1%+146.7%
TTM-4.7%-209.9%+205.2%
YOY-1.8%-234.9%+233.1%
5Y7.7%-392.9%+400.6%
10Y-24.8%-512.4%+487.6%
1.1.2. Return on Assets

Shows how efficient Pharming is using its assets to generate profit.

  • Above 5% is considered healthy¬†but always compare¬†Pharming to the¬†Biotechnology industry mean.
  • -2.8% Return on Assets means that¬†Pharming generated¬†€-0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Pharming Group NV:

  • The MRQ is -2.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -0.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.8%TTM-0.6%-2.2%
TTM-0.6%YOY0.0%-0.6%
TTM-0.6%5Y1.3%-1.9%
5Y1.3%10Y-0.8%+2.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.8%-11.8%+9.0%
TTM-0.6%-11.9%+11.3%
YOY0.0%-11.2%+11.2%
5Y1.3%-13.3%+14.6%
10Y-0.8%-14.7%+13.9%
1.1.3. Return on Equity

Shows how efficient Pharming is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare¬†Pharming to the¬†Biotechnology industry mean.
  • -6.0% Return on Equity means Pharming generated €-0.06¬†for each¬†€1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Pharming Group NV:

  • The MRQ is -6.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -1.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.0%TTM-1.3%-4.8%
TTM-1.3%YOY-0.2%-1.1%
TTM-1.3%5Y3.1%-4.4%
5Y3.1%10Y-17.9%+21.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.0%-14.1%+8.1%
TTM-1.3%-15.2%+13.9%
YOY-0.2%-14.0%+13.8%
5Y3.1%-18.8%+21.9%
10Y-17.9%-19.4%+1.5%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of Pharming Group NV.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Pharming is operating .

  • Measures how much profit Pharming makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare¬†Pharming to the¬†Biotechnology industry mean.
  • An Operating Margin of 0.0%¬†means the company generated €0.00 ¬†for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Pharming Group NV:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM3.3%-3.3%
TTM3.3%YOY1.0%+2.2%
TTM3.3%5Y17.4%-14.1%
5Y17.4%10Y-19.6%+37.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--346.7%+346.7%
TTM3.3%-218.9%+222.2%
YOY1.0%-238.4%+239.4%
5Y17.4%-400.7%+418.1%
10Y-19.6%-514.0%+494.4%
1.2.2. Operating Ratio

Measures how efficient Pharming is keeping operating costs low.

  • Below 1 is considered healthy (always compare to¬†Biotechnology industry mean).
  • An Operation Ratio of 1.44 means that the operating costs are €1.44 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Pharming Group NV:

  • The MRQ is 1.444. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.128. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.444TTM1.128+0.317
TTM1.128YOY1.002+0.125
TTM1.1285Y0.882+0.246
5Y0.88210Y1.222-0.340
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4443.003-1.559
TTM1.1283.247-2.119
YOY1.0023.454-2.452
5Y0.8825.124-4.242
10Y1.2226.570-5.348
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of Pharming Group NV.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Pharming is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to¬†Biotechnology industry mean).
  • A Current Ratio of 1.43¬†means the company has €1.43 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Pharming Group NV:

  • The MRQ is 1.431. The company is just able to pay all its short-term debts.
  • The TTM is 3.516. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ1.431TTM3.516-2.085
TTM3.516YOY4.945-1.429
TTM3.5165Y3.988-0.472
5Y3.98810Y3.117+0.871
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4313.793-2.362
TTM3.5164.066-0.550
YOY4.9454.958-0.013
5Y3.9885.996-2.008
10Y3.1176.335-3.218
1.3.2. Quick Ratio

Measures if Pharming is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but¬†always compare¬†Pharming to the¬†Biotechnology industry mean.
  • A Quick Ratio of 0.91¬†means the company can pay off €0.91 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Pharming Group NV:

  • The MRQ is 0.911. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 3.803. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ0.911TTM3.803-2.892
TTM3.803YOY4.204-0.401
TTM3.8035Y3.662+0.140
5Y3.66210Y2.627+1.035
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9113.192-2.281
TTM3.8033.581+0.222
YOY4.2044.835-0.631
5Y3.6625.948-2.286
10Y2.6276.457-3.830
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of Pharming Group NV.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Pharming assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare¬†Pharming to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.53¬†means that Pharming assets are¬†financed with 53.4% credit (debt) and the remaining percentage (100% - 53.4%)¬†is financed by its owners/shareholders.¬†

Let's take a look of the Debt to Asset Ratio trends of Pharming Group NV:

  • The MRQ is 0.534. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.528. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.534TTM0.528+0.005
TTM0.528YOY0.504+0.024
TTM0.5285Y0.542-0.014
5Y0.54210Y0.618-0.076
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5340.328+0.206
TTM0.5280.339+0.189
YOY0.5040.286+0.218
5Y0.5420.367+0.175
10Y0.6180.383+0.235
1.4.2. Debt to Equity Ratio

Measures if Pharming is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but¬†always compare¬†Pharming to the¬†Biotechnology industry mean.
  • A Debt to Equity ratio of 114.5% means that company has €1.14 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Pharming Group NV:

  • The MRQ is 1.145. The company is able to pay all its debts with equity. +1
  • The TTM is 1.121. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.145TTM1.121+0.024
TTM1.121YOY1.021+0.100
TTM1.1215Y1.201-0.080
5Y1.20110Y2.717-1.516
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1450.363+0.782
TTM1.1210.412+0.709
YOY1.0210.367+0.654
5Y1.2010.438+0.763
10Y2.7170.476+2.241
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of Pharming Group NV

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures¬†how much money you pay¬†for each share for¬†every €1 in earnings Pharming generates.

  • Above 15 is considered overpriced but¬†always compare¬†Pharming to the¬†Biotechnology industry mean.
  • A PE ratio of -15.02 means the investor is paying €-15.02¬†for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Pharming Group NV:

  • The EOD is -11.278. Based on the earnings, the company is expensive. -2
  • The MRQ is -15.023. Based on the earnings, the company is expensive. -2
  • The TTM is 34.513. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD-11.278MRQ-15.023+3.745
MRQ-15.023TTM34.513-49.536
TTM34.513YOY-0.311+34.824
TTM34.5135Y-4.277+38.790
5Y-4.27710Y-0.578-3.699
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-11.278-2.652-8.626
MRQ-15.023-3.015-12.008
TTM34.513-2.881+37.394
YOY-0.311-3.574+3.263
5Y-4.277-6.225+1.948
10Y-0.578-6.348+5.770
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Pharming Group NV:

  • The EOD is -18.169. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -24.202. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 9.916. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-18.169MRQ-24.202+6.033
MRQ-24.202TTM9.916-34.118
TTM9.916YOY23.718-13.802
TTM9.9165Y54.494-44.578
5Y54.49410Y22.694+31.800
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-18.169-3.251-14.918
MRQ-24.202-3.787-20.415
TTM9.916-3.794+13.710
YOY23.718-5.044+28.762
5Y54.494-8.020+62.514
10Y22.694-8.669+31.363
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Pharming is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy¬†(always compare to Biotechnology industry mean).
  • A PB ratio of 3.63 means the investor is paying €3.63¬†for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Pharming Group NV:

  • The EOD is 2.727. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.632. Based on the equity, the company is fair priced.
  • The TTM is 3.821. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.727MRQ3.632-0.905
MRQ3.632TTM3.821-0.188
TTM3.821YOY3.843-0.023
TTM3.8215Y4.753-0.932
5Y4.75310Y10.408-5.655
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.7271.991+0.736
MRQ3.6322.271+1.361
TTM3.8212.296+1.525
YOY3.8432.385+1.458
5Y4.7533.670+1.083
10Y10.4084.162+6.246
2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Pharming Group NV compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0170.002-847%0.004-566%0.009-292%0.007-351%
Book Value Per Share--0.2810.284-1%0.268+5%0.236+19%0.140+101%
Current Ratio--1.4313.516-59%4.945-71%3.988-64%3.117-54%
Debt To Asset Ratio--0.5340.528+1%0.504+6%0.542-2%0.618-14%
Debt To Equity Ratio--1.1451.121+2%1.021+12%1.201-5%2.717-58%
Dividend Per Share----0%-0%-0%-0%
Eps---0.017-0.004-78%-0.001-95%0.005-477%0.000-16034%
Free Cash Flow Per Share---0.011-0.001-89%-0.001-91%0.008-225%0.006-267%
Free Cash Flow To Equity Per Share---0.014-0.001-89%-0.003-82%0.008-277%0.008-283%
Gross Profit Margin--1.000-0.890+189%1.185-16%0.454+120%0.585+71%
Intrinsic Value_10Y_max--0.184--------
Intrinsic Value_10Y_min---0.712--------
Intrinsic Value_1Y_max--0.024--------
Intrinsic Value_1Y_min---0.009--------
Intrinsic Value_3Y_max--0.068--------
Intrinsic Value_3Y_min---0.081--------
Intrinsic Value_5Y_max--0.107--------
Intrinsic Value_5Y_min---0.212--------
Market Cap515180082.240-33%686233640.947730914564.893-6%708777592.400-3%709658053.178-3%538548309.597+27%
Net Profit Margin---0.224-0.047-79%-0.018-92%0.077-390%-0.248+11%
Operating Margin---0.033-100%0.010-100%0.174-100%-0.1960%
Operating Ratio--1.4441.128+28%1.002+44%0.882+64%1.222+18%
Pb Ratio2.727-33%3.6323.821-5%3.843-5%4.753-24%10.408-65%
Pe Ratio-11.278+25%-15.02334.513-144%-0.311-98%-4.277-72%-0.578-96%
Price Per Share0.765-33%1.0191.085-6%1.032-1%1.041-2%0.793+29%
Price To Free Cash Flow Ratio-18.169+25%-24.2029.916-344%23.718-202%54.494-144%22.694-207%
Price To Total Gains Ratio-45.545+25%-60.668222.383-127%1309.935-105%329.182-118%130.676-146%
Quick Ratio--0.9113.803-76%4.204-78%3.662-75%2.627-65%
Return On Assets---0.028-0.006-79%0.000-20625%0.013-311%-0.008-70%
Return On Equity---0.060-0.013-79%-0.002-97%0.031-292%-0.179+196%
Total Gains Per Share---0.0170.002-847%0.004-566%0.009-292%0.007-351%
Usd Book Value--205937997.870208752902.160-1%200969416.808+2%174990806.849+18%103477429.665+99%
Usd Book Value Change Per Share---0.0180.002-847%0.004-566%0.010-292%0.007-351%
Usd Book Value Per Share--0.3060.310-1%0.292+5%0.257+19%0.152+101%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.018-0.004-78%-0.001-95%0.005-477%0.000-16034%
Usd Free Cash Flow---7726737.282-873220.310-89%-578480.331-93%6327359.570-222%4684949.737-265%
Usd Free Cash Flow Per Share---0.011-0.001-89%-0.001-91%0.009-225%0.007-267%
Usd Free Cash Flow To Equity Per Share---0.015-0.002-89%-0.003-82%0.009-277%0.008-283%
Usd Market Cap561546289.642-33%747994668.632796696875.733-6%772567575.716-3%773527277.964-3%587017657.460+27%
Usd Price Per Share0.834-33%1.1111.182-6%1.125-1%1.134-2%0.864+29%
Usd Profit---12447576.768-2696908.302-78%-498733.043-96%3981533.626-413%139416.300-9028%
Usd Revenue--55584110.07664588053.932-14%50384786.859+10%53591954.610+4%35645485.829+56%
Usd Total Gains Per Share---0.0180.002-847%0.004-566%0.010-292%0.007-351%
 EOD+3 -5MRQTTM+5 -29YOY+8 -265Y+11 -2310Y+15 -18

3.2. Fundamental Score

Let's check the fundamental score of Pharming Group NV based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-11.278
Price to Book Ratio (EOD)Between0-12.727
Net Profit Margin (MRQ)Greater than0-0.224
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.911
Current Ratio (MRQ)Greater than11.431
Debt to Asset Ratio (MRQ)Less than10.534
Debt to Equity Ratio (MRQ)Less than11.145
Return on Equity (MRQ)Greater than0.15-0.060
Return on Assets (MRQ)Greater than0.05-0.028
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Pharming Group NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.805
Ma 20Greater thanMa 500.772
Ma 50Greater thanMa 1000.791
Ma 100Greater thanMa 2000.885
OpenGreater thanClose0.792
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets441,668
Total Liabilities235,723
Total Stockholder Equity205,945
 As reported
Total Liabilities 235,723
Total Stockholder Equity+ 205,945
Total Assets = 441,668

Assets

Total Assets441,668
Total Current Assets296,550
Long-term Assets145,118
Total Current Assets
Cash And Cash Equivalents 51,892
Short-term Investments 150,078
Net Receivables 38,697
Inventory 55,883
Total Current Assets  (as reported)296,550
Total Current Assets  (calculated)296,550
+/-0
Long-term Assets
Property Plant Equipment 31,862
Long Term Investments 7,681
Long-term Assets Other 1,500
Long-term Assets  (as reported)145,118
Long-term Assets  (calculated)41,043
+/- 104,075

Liabilities & Shareholders' Equity

Total Current Liabilities207,285
Long-term Liabilities28,438
Total Stockholder Equity205,945
Total Current Liabilities
Short Long Term Debt 134,889
Accounts payable 68,516
Total Current Liabilities  (as reported)207,285
Total Current Liabilities  (calculated)203,405
+/- 3,880
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt32,318
Long-term Liabilities  (as reported)28,438
Long-term Liabilities  (calculated)32,318
+/- 3,880
Total Stockholder Equity
Total Stockholder Equity (as reported)205,945
Total Stockholder Equity (calculated)0
+/- 205,945
Other
Capital Stock7,681
Common Stock Shares Outstanding 673,438
Net Debt 82,997
Net Invested Capital 340,834
Net Working Capital 89,265
Property Plant and Equipment Gross 31,862



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-31
> Total Assets 
0
0
0
80,066
82,432
87,869
74,075
49,592
46,405
43,127
37,683
32,006
36,952
0
20,095
22,276
37,634
37,367
32,005
43,370
45,665
55,928
51,724
67,754
58,207
56,260
69,943
63,058
63,209
59,697
54,812
133,338
140,457
145,242
164,331
199,379
210,432
209,697
223,936
245,446
224,106
233,988
241,593
255,634
335,220
356,646
374,932
419,116
408,566
412,023
400,906
350,552
392,798
393,898
382,323
425,797
422,996
429,805
436,467
462,854
441,668
441,668462,854436,467429,805422,996425,797382,323393,898392,798350,552400,906412,023408,566419,116374,932356,646335,220255,634241,593233,988224,106245,446223,936209,697210,432199,379164,331145,242140,457133,33854,81259,69763,20963,05869,94356,26058,20767,75451,72455,92845,66543,37032,00537,36737,63422,27620,095036,95232,00637,68343,12746,40549,59274,07587,86982,43280,066000
   > Total Current Assets 
0
0
0
40,934
45,588
54,752
40,056
38,897
33,832
26,785
22,452
17,058
22,066
0
8,652
11,174
25,069
27,204
22,272
33,968
36,673
47,054
43,765
59,758
51,327
48,891
62,631
55,859
55,797
51,529
46,014
65,405
70,641
69,912
86,487
105,875
116,431
121,952
134,264
132,052
114,197
115,081
111,367
119,302
197,325
219,750
232,020
263,632
261,823
251,258
242,193
220,085
250,948
256,980
252,048
277,500
266,056
278,573
291,737
316,342
296,550
296,550316,342291,737278,573266,056277,500252,048256,980250,948220,085242,193251,258261,823263,632232,020219,750197,325119,302111,367115,081114,197132,052134,264121,952116,431105,87586,48769,91270,64165,40546,01451,52955,79755,85962,63148,89151,32759,75843,76547,05436,67333,96822,27227,20425,06911,1748,652022,06617,05822,45226,78533,83238,89740,05654,75245,58840,934000
       Cash And Cash Equivalents 
0
0
0
22,814
28,608
39,635
22,897
13,701
20,450
14,339
11,860
4,895
10,535
0
1,886
6,974
23,182
16,977
17,139
23,431
25,581
35,820
29,987
41,569
32,623
27,790
39,216
34,595
31,173
23,820
18,807
33,538
29,235
28,595
45,075
70,371
72,070
75,776
82,531
91,868
73,292
72,638
68,892
74,266
147,610
171,829
181,738
205,486
206,254
188,385
183,308
169,335
189,674
189,964
188,703
207,342
184,780
192,373
54,653
61,741
51,892
51,89261,74154,653192,373184,780207,342188,703189,964189,674169,335183,308188,385206,254205,486181,738171,829147,61074,26668,89272,63873,29291,86882,53175,77672,07070,37145,07528,59529,23533,53818,80723,82031,17334,59539,21627,79032,62341,56929,98735,82025,58123,43117,13916,97723,1826,9741,886010,5354,89511,86014,33920,45013,70122,89739,63528,60822,814000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-737
-519
-662
-568
-700
-989
0
0
0
0
0
0
0
0
0
0
0
142,912
151,683
150,078
150,078151,683142,91200000000000-989-700-568-662-519-73700000000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
3,277
241
306
329
830
388
0
369
538
859
7,085
606
849
807
1,775
2,115
1,715
2,571
4,774
4,652
3,272
4,394
6,173
6,588
11,975
21,208
21,329
20,283
12,217
17,717
19,395
27,388
18,304
25,585
27,997
29,524
26,277
33,710
29,676
31,049
31,936
32,883
37,568
32,808
26,454
31,445
32,878
28,828
27,619
32,931
33,158
40,521
42,615
38,697
38,69742,61540,52133,15832,93127,61928,82832,87831,44526,45432,80837,56832,88331,93631,04929,67633,71026,27729,52427,99725,58518,30427,38819,39517,71712,21720,28321,32921,20811,9756,5886,1734,3943,2724,6524,7742,5711,7152,1151,7758078496067,08585953836903888303293062413,2770000000
       Other Current Assets 
0
0
0
1,994
1,828
1,463
1,912
9,932
584
684
919
2,804
1,161
0
1,298
668
-2,838
247
618
2,008
0
0
0
144
0
0
0
227
0
0
0
974
0
0
0
1,077
0
0
0
1,813
0
0
0
2,279
0
0
0
4,081
-1
830
846
200
222
209
412
213
218
0
212
3,543
0
03,5432120218213412209222200846830-14,0810002,2790001,8130001,0770009740002270001440002,008618247-2,8386681,29801,1612,8049196845849,9321,9121,4631,8281,994000
   > Long-term Assets 
0
0
0
39,133
36,844
33,116
34,020
10,694
12,573
16,342
15,231
14,948
14,886
0
11,443
11,102
9,727
10,163
9,733
9,402
8,992
8,873
7,960
7,995
6,880
7,369
7,312
7,199
7,412
8,168
8,798
67,933
69,816
75,330
77,845
93,504
94,001
87,745
89,672
113,394
109,909
118,907
130,227
136,333
137,895
136,896
142,912
155,484
146,743
160,765
158,713
130,467
141,850
136,918
130,275
148,297
156,940
151,232
144,730
146,512
145,118
145,118146,512144,730151,232156,940148,297130,275136,918141,850130,467158,713160,765146,743155,484142,912136,896137,895136,333130,227118,907109,909113,39489,67287,74594,00193,50477,84575,33069,81667,9338,7988,1687,4127,1997,3127,3696,8807,9957,9608,8738,9929,4029,73310,1639,72711,10211,443014,88614,94815,23116,34212,57310,69434,02033,11636,84439,133000
       Property Plant Equipment 
0
0
0
7,508
6,976
6,348
7,377
8,913
9,350
13,189
12,416
12,400
12,405
0
9,326
9,427
8,858
8,761
8,906
8,600
8,238
8,169
7,329
6,807
5,836
6,302
6,257
6,189
6,379
6,535
6,629
6,355
6,884
8,127
9,176
9,878
9,826
9,586
9,642
9,611
13,664
17,080
16,151
16,278
15,739
15,781
19,386
21,687
21,881
37,646
37,893
29,262
31,897
29,958
27,782
39,145
40,772
39,346
37,482
33,466
31,862
31,86233,46637,48239,34640,77239,14527,78229,95831,89729,26237,89337,64621,88121,68719,38615,78115,73916,27816,15117,08013,6649,6119,6429,5869,8269,8789,1768,1276,8846,3556,6296,5356,3796,1896,2576,3025,8366,8077,3298,1698,2388,6008,9068,7618,8589,4279,326012,40512,40012,41613,1899,3508,9137,3776,3486,9767,508000
       Goodwill 
0
0
0
6,178
5,789
4,784
2,016
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-9,867
0
3,447
-1,438
0
5,905
6,137
3,779
0
0
003,7796,1375,9050-1,4383,4470-9,867000000000000000000000000000000000000000000002,0164,7845,7896,178000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,377
5,517
5,307
5,515
5,616
5,682
5,796
5,722
6,104
8,630
8,787
7,403
11,631
10,776
9,731
9,767
9,650
9,239
10,398
7,681
7,68110,3989,2399,6509,7679,73110,77611,6317,4038,7878,6306,1045,7225,7965,6825,6165,5155,3075,5175,37700000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
25,195
23,844
21,770
24,387
1,547
1,580
1,556
1,400
0
1,258
0
0
708
0
0
0
559
0
0
0
945
0
0
0
792
0
0
0
59,610
56,148
55,855
56,735
67,940
56,272
55,843
56,322
59,981
52,062
51,516
67,806
79,318
0
0
0
94,233
0
0
0
83,834
0
72,319
71,561
75,121
69,701
67,276
66,070
71,267
0
071,26766,07067,27669,70175,12171,56172,319083,83400094,23300079,31867,80651,51652,06259,98156,32255,84356,27267,94056,73555,85556,14859,610000792000945000559000708001,25801,4001,5561,5801,54724,38721,77023,84425,195000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,838
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,743
0
1,748
0
12,002
11,757
12,551
40,529
33,642
32,665
0
35,162
27,620
24,854
22,585
30,815
0
0
18,802
22,488
21,229
19,563
21,594
24,300
30,795
28,823
0
0
0
00028,82330,79524,30021,59419,56321,22922,48818,8020030,81522,58524,85427,62035,162032,66533,64240,52912,55111,75712,00201,74802,7430000000000000002,8380000000000000000
> Total Liabilities 
0
0
0
60,992
74,575
74,008
49,632
36,159
34,723
37,213
34,688
33,545
41,694
0
34,360
32,396
45,362
38,145
34,155
36,452
35,885
39,297
31,573
31,464
26,509
24,975
41,163
36,995
39,371
39,500
38,004
104,451
109,531
137,504
157,037
176,822
171,463
162,680
167,959
174,809
146,544
145,882
142,604
138,376
207,699
213,173
214,963
235,389
222,540
213,865
207,375
180,341
198,777
194,228
182,069
221,159
223,653
229,433
226,525
244,073
235,723
235,723244,073226,525229,433223,653221,159182,069194,228198,777180,341207,375213,865222,540235,389214,963213,173207,699138,376142,604145,882146,544174,809167,959162,680171,463176,822157,037137,504109,531104,45138,00439,50039,37136,99541,16324,97526,50931,46431,57339,29735,88536,45234,15538,14545,36232,39634,360041,69433,54534,68837,21334,72336,15949,63274,00874,57560,992000
   > Total Current Liabilities 
0
0
0
51,966
66,014
62,727
25,454
12,879
10,719
9,676
9,677
10,544
18,931
0
13,147
11,860
26,279
19,354
14,297
17,848
18,218
22,460
16,765
18,086
15,255
13,976
15,649
14,732
18,550
20,537
20,517
54,034
65,817
39,421
65,908
70,216
72,889
74,428
100,265
94,485
69,928
75,011
98,582
114,130
48,969
49,362
42,858
76,969
73,705
47,838
46,717
41,265
45,151
49,194
46,694
59,698
59,003
64,952
68,058
77,968
207,285
207,28577,96868,05864,95259,00359,69846,69449,19445,15141,26546,71747,83873,70576,96942,85849,36248,969114,13098,58275,01169,92894,485100,26574,42872,88970,21665,90839,42165,81754,03420,51720,53718,55014,73215,64913,97615,25518,08616,76522,46018,21817,84814,29719,35426,27911,86013,147018,93110,5449,6779,67610,71912,87925,45462,72766,01451,966000
       Short-term Debt 
0
0
0
39,402
48,689
42,092
15,148
0
0
0
0
1,579
5,536
0
1,207
1,184
13,463
9,326
3,959
1,058
670
644
586
761
329
237
2,270
3,619
4,870
6,195
6,613
27,764
33,581
12,920
20,165
26,663
34,798
40,972
42,049
40,606
39,559
40,486
39,968
53,248
1,813
1,740
2,048
4,008
4,960
4,624
4,517
3,792
4,324
4,120
3,950
5,233
5,749
5,653
5,518
5,440
0
05,4405,5185,6535,7495,2333,9504,1204,3243,7924,5174,6244,9604,0082,0481,7401,81353,24839,96840,48639,55940,60642,04940,97234,79826,66320,16512,92033,58127,7646,6136,1954,8703,6192,2702373297615866446701,0583,9599,32613,4631,1841,20705,5361,579000015,14842,09248,68939,402000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
67,393
65,590
90,494
16,908
21,962
27,945
35,174
35,924
35,235
34,963
33,607
34,432
45,590
0
0
0
1,661
2,607
1,657
1,657
1,657
1,844
1,728
1,627
1,768
1,805
1,797
1,748
1,824
134,889
134,8891,8241,7481,7971,8051,7681,6271,7281,8441,6571,6571,6572,6071,66100045,59034,43233,60734,96335,23535,92435,17427,94521,96216,90890,49465,59067,3930000000000000000000000000000000
       Accounts payable 
0
0
0
0
11,280
9,471
0
0
0
0
0
0
0
0
7,560
1,489
5,754
3,556
4,765
5,561
9,791
4,478
7,446
3,579
9,301
9,061
8,979
1,111
10,515
11,340
10,898
5,944
18,040
17,161
19,997
11,313
35,714
30,933
36,216
7,598
29,306
33,471
37,491
5,994
46,993
47,414
40,648
13,491
43,603
43,142
42,147
37,473
40,827
45,074
42,744
54,465
53,254
59,299
62,540
16,022
68,516
68,51616,02262,54059,29953,25454,46542,74445,07440,82737,47342,14743,14243,60313,49140,64847,41446,9935,99437,49133,47129,3067,59836,21630,93335,71411,31319,99717,16118,0405,94410,89811,34010,5151,1118,9799,0619,3013,5797,4464,4789,7915,5614,7653,5565,7541,4897,560000000009,47111,2800000
       Other Current Liabilities 
0
0
0
12,564
6,045
5,216
10,307
12,879
10,719
9,676
9,677
8,965
13,395
0
3,411
6,627
4,583
2,393
2,604
8,191
4,731
14,337
5,941
11,071
3,242
2,203
1,917
7,590
664
547
599
19,334
13,258
8,413
24,800
31,275
1,387
1,598
21,070
45,366
165
144
20,249
20,278
163
208
162
25,219
25,142
71
53
1,539
0
3,933
4,031
47,578
5,300
5,180
5,219
56,506
0
056,5065,2195,1805,30047,5784,0313,93301,539537125,14225,21916220816320,27820,24914416545,36621,0701,5981,38731,27524,8008,41313,25819,3345995476647,5901,9172,2033,24211,0715,94114,3374,7318,1912,6042,3934,5836,6273,411013,3958,9659,6779,67610,71912,87910,3075,2166,04512,564000
   > Long-term Liabilities 
0
0
0
9,026
8,561
11,281
24,178
23,280
24,004
27,537
25,011
23,002
22,763
0
21,213
20,536
19,082
18,792
19,858
18,604
17,667
16,837
14,808
13,379
11,254
10,998
25,514
22,263
20,820
18,963
17,487
50,416
43,714
98,083
91,129
106,606
98,575
88,252
67,694
80,324
76,616
70,871
44,022
24,246
158,729
163,812
172,106
158,420
148,834
166,027
160,657
139,076
153,626
145,034
135,375
161,461
164,650
164,481
158,467
166,105
28,438
28,438166,105158,467164,481164,650161,461135,375145,034153,626139,076160,657166,027148,834158,420172,106163,812158,72924,24644,02270,87176,61680,32467,69488,25298,575106,60691,12998,08343,71450,41617,48718,96320,82022,26325,51410,99811,25413,37914,80816,83717,66718,60419,85818,79219,08220,53621,213022,76323,00225,01127,53724,00423,28024,17811,2818,5619,026000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,944
6,742
6,541
6,341
29,786
29,586
28,222
16,640
32,788
31,985
32,325
16,222
17,282
18,298
18,298
18,298
173
161
159
333
165
162
152
143
0
0
0
0
0
0
00000014315216216533315916117318,29818,29818,29817,28216,22232,32531,98532,78816,64028,22229,58629,7866,3416,5416,7426,9440000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
791
0
0
0
3,588
0
0
0
2,237
0
0
0
4,304
0
0
0
4,443
0
0
0
266
0
0
0
0
0
0
0
0
0
0000000002660004,4430004,3040002,2370003,5880007910000000000000000000000000000000
> Total Stockholder Equity
0
0
0
19,074
7,858
13,860
16,773
14,449
11,682
5,914
2,995
-1,540
-4,742
0
-14,265
-10,120
-7,727
-778
-2,150
6,918
9,780
16,631
20,152
36,289
31,698
31,285
28,779
26,063
23,838
20,197
16,808
28,887
30,926
7,738
7,294
22,557
38,968
47,017
55,977
70,637
77,562
88,106
98,989
117,258
127,522
143,473
159,968
183,727
186,026
198,158
193,531
170,211
194,021
199,670
200,254
204,638
199,343
200,372
209,942
218,781
205,945
205,945218,781209,942200,372199,343204,638200,254199,670194,021170,211193,531198,158186,026183,727159,968143,473127,522117,25898,98988,10677,56270,63755,97747,01738,96822,5577,2947,73830,92628,88716,80820,19723,83826,06328,77931,28531,69836,28920,15216,6319,7806,918-2,150-778-7,727-10,120-14,2650-4,742-1,5402,9955,91411,68214,44916,77313,8607,85819,074000
   Common Stock
0
0
0
110,681
103,708
14,863
19,559
23,208
26,043
26,703
26,627
26,447
29,961
0
11,410
13,347
1,692
2,735
3,102
4,620
5,146
5,531
5,173
4,958
4,419
4,578
4,594
4,504
4,675
4,589
4,629
4,792
5,118
5,536
6,107
6,946
7,418
7,057
7,172
7,109
6,987
7,114
6,885
7,072
7,004
7,172
7,492
7,857
7,183
7,254
7,259
6,425
7,468
7,469
7,482
7,509
7,518
7,540
7,650
7,669
0
07,6697,6507,5407,5187,5097,4827,4697,4686,4257,2597,2547,1837,8577,4927,1727,0047,0726,8857,1146,9877,1097,1727,0577,4186,9466,1075,5365,1184,7924,6294,5894,6754,5044,5944,5784,4194,9585,1735,5315,1464,6203,1022,7351,69213,34711,410029,96126,44726,62726,70326,04323,20819,55914,863103,708110,681000
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-6,636
0
0
0
-6,796
0
0
0
-7,569
0
0
0
18,706
18,208
18,595
19,388
20,539
20,662
20,700
20,969
44
45
44
47
72
71
73
72
63
43
-700
-494
-1,125
-2,911
-1,270
-985
1,884
1,729
1,998
1,277
4,165
4,144
4,284
4,980
5,339
11,337
14,671
9,864
1,917
-910
-12,607
-24,145
-8,737
-4,906
-6,037
-10,915
-2,057
0
0-2,057-10,915-6,037-4,906-8,737-24,145-12,607-9101,9179,86414,67111,3375,3394,9804,2844,1444,1651,2771,9981,7291,884-985-1,270-2,911-1,125-494-7004363727371724744454420,96920,70020,66220,53919,38818,59518,20818,706000-7,569000-6,796000-6,636000
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
204,766
-95,850
-1,003
-2,786
241,423
-14,361
-20,789
-23,632
244,389
-34,704
0
313,101
231,866
236,909
243,270
245,885
254,901
272,491
281,216
282,261
282,260
282,385
282,428
281,841
283,396
283,517
283,528
283,538
301,876
308,320
310,907
316,858
370,220
381,042
387,760
391,023
387,525
387,956
389,310
391,151
392,266
394,255
396,033
396,231
396,799
382,438
380,856
390,928
399,850
457,961
458,357
459,450
462,297
463,222
464,363
475,983
478,431
0
0478,431475,983464,363463,222462,297459,450458,357457,961399,850390,928380,856382,438396,799396,231396,033394,255392,266391,151389,310387,956387,525391,023387,760381,042370,220316,858310,907308,320301,876283,538283,528283,517283,396281,841282,428282,385282,260282,261281,216272,491254,901245,885243,270236,909231,866313,1010-34,704244,389-23,632-20,789-14,361241,423-2,786-1,003-95,850204,766000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.